表紙:潜在性結核感染症 (LTBI) 検査の世界市場 - 考察と予測、COVID-19の潜在的影響:2021年~2025年
市場調査レポート
商品コード
997394

潜在性結核感染症 (LTBI) 検査の世界市場 - 考察と予測、COVID-19の潜在的影響:2021年~2025年

Global Latent Tuberculosis Infection (LTBI) Testing Market: Insights & Forecast with Potential Impact of COVID-19 (2021-2025)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 116 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
潜在性結核感染症 (LTBI) 検査の世界市場 - 考察と予測、COVID-19の潜在的影響:2021年~2025年
出版日: 2021年03月23日
発行: Koncept Analytics
ページ情報: 英文 116 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の潜在性結核感染症 (LTBI) 検査市場は、2025年には22億米ドルに達し、2021年~2025年のCAGRで5.89%の成長が予測されています。高齢者人口の増加、結核に対する意識の高まり、たばこ消費量の急増、都市化によるモニタリング・スクリーニング、HIVの蔓延、医薬品の研究開発の急増などの要因が、市場の成長を促進すると予想されています。

当レポートでは、世界の潜在性結核感染症 (LTBI) 検査市場について調査分析し、市場概要、地域別・国別の市場分析、市場力学、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 市場概要

  • 結核 (TB)
  • 結核の種類 (TB)
  • 潜在性結核感染症 (LTBI)
  • 潜在性結核の危険因子
  • 潜在性結核感染症 (LTBI) 検査の種類
  • 潜在性結核感染症 (LTBI) 検査セグメンテーション

第2章 COVID-19の影響

  • 世界経済への影響
  • 個別のモビリティ・リソース可用性に対するCOVID-19の影響
  • 高齢者・潜在性結核感染症治療に対するCOVID-19の高リスク
  • 貧困への影響

第3章 世界の潜在性結核感染症 (LTBI) 検査市場

  • 世界のLTBI検査市場予測:金額別
  • 世界のLTBI検査市場金額:タイプ別
    • ツベルクリン皮膚検査:金額別
    • インターフェロンガンマリリースアッセイ (IGRA) :金額別
  • 世界のLTBI検査市場金額:地域別
  • 世界のLTBI検査市場予測:数量別
  • 世界のLTBI検査市場数量:タイプ別
    • ツベルクリン皮膚検査:数量別
    • インターフェロンガンマリリースアッセイ (IGRA) :数量別
  • 世界のLTBI検査市場数量:地域別

第4章 地域別の潜在性結核感染症 (LTBI) 検査市場

  • 米国
  • 中国
  • アジア太平洋地域 (日本・中国を除く)
  • 欧州・中東
  • ラテンアメリカ
  • 日本

第5章 市場力学

  • 成長促進要因
  • 主要動向と開発
  • 課題

第6章 競合情勢

  • 世界の市場
    • 主要企業の収益比較
    • 主要企業の時価総額の比較
    • 主要企業のR&D比較

第7章 企業プロファイル

  • Qiagen N.V.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Roche Holding AG
  • Thermo Fisher Scientific Inc. Inc
  • Oxford Immunotec Global PLC
図表

List of Figures

  • Symptoms of TB
  • Types of TB
  • Risk Factors of Latent Tuberculosis
  • Types of Latent Tuberculosis Infection Testing
  • Latent Tuberculosis Infection Testing Segmentation
  • Global Poverty Rate (2014-2021)
  • Global LTBI Testing Market Forecast by Value (2018-2025)
  • Global LTBI Testing Market Value by Type (2020)
  • Global Tuberculin Skin Test LTBI Testing Market Forecast by Value (2018-2025)
  • Global Interferon Gamma Released Assay (IGRA) LTBI Testing Market Forecast by Value (2018-2025)
  • Global LTBI Testing Market Value by Region (2020)
  • Global LTBI Testing Market Forecast by Volume (2018-2025)
  • Global LTBI Testing Market Volume by Type (2020)
  • Global Tuberculin Skin Test LTBI Testing Market Forecast by Volume (2018-2025)
  • Global Interferon Gamma Released Assay (IGRA) LTBI Testing Market Forecast by Volume (2018-2025)
  • Global LTBI Testing Market Volume by Region (2020)
  • The U.S. LTBI Testing Market Forecast by Value (2018-2025)
  • The U.S. LTBI Testing Market Forecast by Volume (2018-2025)
  • China LTBI Testing Market Forecast by Value (2018-2025)
  • China LTBI Testing Market Forecast by Volume (2018-2025)
  • Asia-Pacific (excluding Japan and China) LTBI Testing Market Forecast by Value (2018-2025)
  • Asia-Pacific (excluding Japan and China) LTBI Testing Market Forecast by Volume (2018-2025)
  • Europe and Middle East LTBI Testing Market Forecast by Value (2018-2025)
  • Europe and Middle East Mark LTBI Testing Market Forecast by Volume (2018-2025)
  • Latin America LTBI Testing Market Forecast by Value (2018-2025)
  • Latin America LTBI Testing Market Forecast by Volume (2018-2025)
  • Japan LTBI Testing Market Forecast by Value (2018-2025)
  • Japan LTBI Testing Market Forecast by Volume (2018-2025)
  • Global Ageing Population - Above 60+ (2021-2030)
  • Global Literacy Rate (2016-2020)
  • Global Cigarette Consumption (2014-2020)
  • Global Urban Population (2010-2030)
  • Total Number of People Living with HIV Worldwide (2015-2020)
  • Global Pharmaceutical Research and Development Expenditures (2021-2030)
  • Global Healthcare Expenditure (1995-2022)
  • The U.S. Funding for Global Tuberculosis (TB) (2016-2021)
  • Qiagen N.V. Net Sales and Net Income (Loss) (2016-2020)
  • Qiagen N.V. Net Sales by Region (2020)
  • Abbott Laboratories Net Sales and Net Earnings (2016-2020)
  • Abbott Laboratories Net Sales by Segment (2020)
  • Abbott Laboratories Net Sales by Region (2020)
  • Becton, Dickinson and Company Revenue and Net Income (2016-2020)
  • Becton, Dickinson and Company Revenue by Segment (2020)
  • Becton, Dickinson and Company Revenue by Region (2020)
  • BioMerieux SA Sales and Net Income (2016-2020)
  • BioMerieux SA Sales by Segment (2020)
  • BioMerieux SA Sales by Region (2020)
  • Roche Holding AG Sales and Net Income (2016-2020)
  • Roche Holding AG Sales by Segment (2020)
  • Roche Holding AG Sales by Region (2020)
  • Thermo Fisher Scientific Inc. Revenue and Net Income (2016-2020)
  • Thermo Fisher Scientific Inc. Revenue by Segment (2020)
  • Thermo Fisher Scientific Inc. Revenue by Region (2020)
  • Oxford Immunotec Global PLC Revenue and Net Income (Loss) (2015-2019)
  • Oxford Immunotec Global PLC Revenue by Segment (2019)
  • Oxford Immunotec Global PLC Revenue by Region (2019)

List of Tables

  • Differences between Latent TB and Active TB
  • Current LPA products and Associated Equipment
  • NAAT-based Technologies
  • Revenue Comparison of Key Players (2019/2020)
  • Market Capitalization Comparison of Key Players (2021)
  • R&D Comparison of Key Players (2019/2020)
目次

The global latent tuberculosis infection (LTBI) testing market is estimated to reach US$2.20 billion in 2025, witnessing growth at a CAGR of 5.89% for the period spanning from 2021 to 2025. The factors such as increase in ageing population, rising awareness of tuberculosis, upsurge in cigarette consumption, urbanization leading to monitoring and screening procedures, surging prevalence of HIV and growth in pharmaceutical research and development. However, growth of the industry will be challenged by multidrug resistant tuberculosis, stringent government regulations, lack of awareness in emerging markets and lack of laboratory facilities. A few notable trends include increasing healthcare expenditure in emerging markets, accelerating TB funding, escalating government initiatives and expansion of advanced and hybrid technologies.

The latent tuberculosis infection testing market can be segmented on the basis of type, named as Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA). TST being a traditional test for tuberculosis diagnosis is the most recommended test. In the global latent tuberculosis testing market, the tuberculin skin test segment accounted for the higher share in 2020.

The fastest growing regional market is the U.S. due to increasing public awareness about diagnosis and treatment of the disease, growing healthcare expenditure on diagnosis and treatment of LTBI, expanding urbanization, accelerating TB funding. China, Japan and Europe and Middle East are emerging markets where growth lies in rising geriatric population, government expenditure on disease related initiatives and growing prevalence of HIV in the region.

Scope of the report:

  • The report provides a comprehensive analysis of the global LTBI testing market segmented on the basis of type and region.
  • The major regional markets (Europe and Middle East, Asia Pacific (Excluding Japan and China) and Latin America) have been analyzed, along with country coverage of the U.S., China and Japan.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, BioMerieux SA, Qiagen N.V. and Oxford Immunotec Global PLC) are also presented in detail.

Key Target Audience:

  • Latent Tuberculosis Infection (LTBI) Testing Devices Manufacturers
  • Raw Material/Component Suppliers
  • End Users (Physician Offices, Hospitals, Healthcare Clinics)
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Tuberculosis (TB)
  • 1.2 Types of Tuberculosis (TB)
  • 1.3 Latent Tuberculosis Infection (LTBI)
  • 1.4 Risk Factors of Latent Tuberculosis
  • 1.5 Types of Latent Tuberculosis Infection Testing
  • 1.6 Latent Tuberculosis Infection Testing Segmentation

2. Impact of COVID-19

  • 2.1 Impact on Global Economy
  • 2.2 Impact of COVID-19 on Individual Mobility & Resource Availability
  • 2.3 Higher Risk of COVID-19 on Geriatric Population & Latent TB Treatment
  • 2.4 Effect on Poverty

3. Global LTBI Testing Market

  • 3.1 Global LTBI Testing Market Forecast by Value
  • 3.2 Global LTBI Testing Market Value by Type
    • 3.2.1 Global Tuberculin Skin Test LTBI Testing Market Forecast by Value
    • 3.2.2 Global Interferon Gamma Released Assay (IGRA) LTBI Testing Market Forecast by Value
  • 3.3 Global LTBI Testing Market Value by Region
  • 3.4 Global LTBI Testing Market Forecast by Volume
  • 3.5 Global LTBI Testing Market Volume by Type
    • 3.5.1 Global Tuberculin Skin Test LTBI Testing Market Forecast by Volume
    • 3.5.2 Global Interferon Gamma Released Assay (IGRA) LTBI Testing Market Forecast by Volume
  • 3.6 Global LTBI Testing Market Volume by Region

4. Regional LTBI Testing Market

  • 4.1 The U.S.
    • 4.1.1 The U.S. LTBI Testing Market Forecast by Value
    • 4.1.2 The U.S. LTBI Testing Market Forecast by Volume
  • 4.2 China
    • 4.2.1 China LTBI Testing Market Forecast by Value
    • 4.2.2 China LTBI Testing Market Forecast by Volume
  • 4.3 Asia-Pacific (Excluding Japan and China)
    • 4.3.1 Asia-Pacific (excluding Japan and China) LTBI Testing Market Forecast by Value
    • 4.3.2 Asia-Pacific (excluding Japan and China) LTBI Testing Market Forecast by Volume
  • 4.4 Europe and Middle East
    • 4.4.1 Europe and Middle East LTBI Testing Market Forecast by Value
    • 4.4.2 Europe and Middle East LTBI Testing Market Forecast by Volume
  • 4.5 Latin America
    • 4.5.1 Latin America LTBI Testing Market Forecast by Value
    • 4.5.2 Latin America LTBI Testing Market Forecast by Volume
  • 4.6 Japan
    • 4.6.1 Japan LTBI Testing Market Forecast by Value
    • 4.6.2 Japan LTBI Testing Market Forecast by Volume

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Increase in Ageing Population
    • 5.1.2 Rising Awareness of Tuberculosis
    • 5.1.3 Upsurge in Cigarette Consumption
    • 5.1.4 Urbanization leading to Monitoring and Screening Procedures
    • 5.1.5 Surging Prevalence of HIV
    • 5.1.6 Growth in Pharmaceutical Research and Development
  • 5.2 Key Trends & Developments
    • 5.2.1 Increasing Healthcare Expenditure in Emerging Markets
    • 5.2.2 Accelerating TB Funding
    • 5.2.3 Escalating Government Initiatives
    • 5.2.4 Expansion of Advanced and Hybrid Technique
    • 5.2.5 Line Probe Assays (LPAs)
    • 5.2.6 Nucleic Acid Amplification Tests (NAATs)
  • 5.3 Challenges
    • 5.3.1 Multidrug Resistant Tuberculosis (MDR-TB)
    • 5.3.2 Stringent Government Regulations
    • 5.3.3 Lack of Awareness in Emerging Markets
    • 5.3.4 Lack of Laboratory Facilities

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Revenue Comparison of Key Players
    • 6.1.2 Market Capitalization Comparison of Key Players
    • 6.1.3 R&D Comparison of Key Players

7. Company Profiles

  • 7.1 Qiagen N.V.
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Abbott Laboratories
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Becton, Dickinson and Company
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 BioMerieux SA
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Roche Holding AG
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Thermo Fisher Scientific Inc. Inc
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies
  • 7.7 Oxford Immunotec Global PLC
    • 7.7.1 Business Overview
    • 7.7.2 Financial Overview
    • 7.7.3 Business Strategies